Suzhou, China, April 25th, 2025, Korean biopharmaceutical company Genexine and China-based innovative drug developer Starna Therapeutics officially entered into a strategic collaboration. Leveraging cutting-edge lung-targeted LNP delivery technology, the two companies will jointly explore new frontiers in pulmonary disease treatment.

此次合作的核心是星锐医药自主研发的STAR LNP递送技术平台。该平台突破了传统LNP体系易在肝脏富集的技术瓶颈，能够实现核酸药物向肺脏的高效精准递送，为肺部疾病的靶向治疗提供了全新的技术路径。基于这一创新技术平台，双方将联合开展临床前候选分子的筛选验证及CMC生产，并共同推动相关项目进入临床开发阶段。

At the core of this partnership is Starna’s proprietary STAR-LNP delivery platform, which overcomes the technical limitations of traditional LNP systems that tend to accumulate in the liver. Instead, it enables highly efficient and precise delivery of nucleic acid drugs to the lungs, offering a novel technological approach for targeted pulmonary disease therapies. Based on this innovative platform, the two parties will collaborate on preclinical candidate screening and validation, CMC production, and jointly advance projects into clinical development.

Genexine致力于发现和开发具有拯救生命潜力的创新药物，专注于“同类首创（First-in-Class）”和“同类最优（Best-in-Class）”的未来研发管线。在过去的25年里，Genexine建立了强大的创新药物研发管线，目前正致力于四个关键候选药物的商业化进程。依托下一代细胞疗法和个性化癌症疫苗等未来增长引擎，Genexine正处于向全球生物技术公司转型的关键阶段。Genexine与全球合作伙伴密切合作，推进肿瘤药物及联合疗法的临床试验，并在多个科学学术会议上展示了积极的临床研究成果。这些活动提升了市场对其癌症免疫疗法技术商业化潜力的期待和关注。www.genexine.com/en

Genexine is committed to discovering and developing innovative therapeutics with life-saving potential, focusing on first-in-class (FIC) and best-in-class (BIC) future pipelines. Over the past 25 years, Genexine has built a robust pipeline of novel drug candidates and is currently advancing four key programs toward commercialization. With next-generation cell therapies and personalized cancer vaccines as future growth engines, Genexine is at a pivotal stage of transforming into a global biotechnology company. Genexine collaborates closely with global partners to advance clinical trials for oncology drugs and combination therapies, with promising clinical results presented at multiple scientific conferences. These efforts have heightened market anticipation for the commercialization of its cancer immunotherapy technologies. 

星锐医药(Starna Therapeutics) 成立于2021年8月，公司聚焦肝外靶向递送技术，致力于研发以RNA为核心的创新药物，解决未被满足的临床需求。公司在苏州生物医药产业园和上海建立了超4000平米的研发和中试生产基地，打造了围绕化学、mRNA和LNP制剂的核心产业链，切实攻克RNA药物研发的核心难点。公司先后获得多家知名基金参与的数亿元融资，已在mRNA疫苗和创新疗法布局丰富的研发管线，其中呼吸道合胞病毒mRNA疫苗STR-V003已获得FDA临床试验许可，个性化肿瘤疫苗，体内细胞治疗预期于2025年开展IIT临床实验。www.starnatx.com

Starna Therapeutics, founded in August 2021, focuses on extrahepatic-targeted delivery technologies, pioneering RNA-based therapeutics to address unmet clinical needs. The company has established R&D and pilot production facilities spanning over 4,000 sqm in Suzhou Industrial BioBay and Shanghai, building an integrated supply chain encompassing chemistry, mRNA, and LNP formulation to tackle core challenges in RNA drug development. Backed by renowned investors with hundreds of millions in funding, Starna has built a diversified pipeline, including an RSV mRNA vaccine (STR-V003), which has received FDA IND clearance, as well as a personalized cancer vaccine and in vivo cell therapy expected to enter IIT clinical trials by 2025.